Skip to content

Biz News Today

Business News – Direct Source News

  • Home
  • Business News Videos
    • International/National News Videos
  • Directory
  • Links PRs
  • REITS
  • About
  • Contact
    • Sitemap

U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma

  • Home
  • 2022
  • March
  • 18
  • U.S. Food and Drug Administration Approves First LAG-3-Blocking Antibody Combination, Opdualag™ (nivolumab and relatlimab-rmbw), as Treatment for Patients with Unresectable or Metastatic Melanoma

Original Source

On March 18, 2022

Post navigation

Previous PostNOV Announces First Quarter 2022 Earnings Conference Call
Next PostThe Week that Was: March 14 to March 18

Related Post

July 3, 2022
  • Business News

Chubb Life Appoints Jack Chang to Lead Newly Acquired Life Insurance Operations of Cigna in Taiwan

July 3, 2022
  • Business News

Chubb Life Appoints Jee Eun Cho to Lead LINA, its Newly Acquired Life Insurance Operations of Cigna in Korea

July 3, 2022
  • Business News

Chubb Life Announces Gail Costa Will Lead Newly Acquired Life Insurance Operations of Cigna in New Zealand

Copyright © All right reserved
Newslist Created By Rise Themes

Notice: ob_end_flush(): failed to send buffer of zlib output compression (0) in /home/biznews/public_html/wp-includes/functions.php on line 5219